PSMA binding ligand-linker conjugates and methods for using
Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
1. A conjugate having the formula
B-L-D
or a salt thereof, wherein
B is a ligand of PSMA comprising one or more of a carbon-sulfur double bond, a phosphorus-sulfur double bond, a phosphorus-sulfur single bond, a thioester, or a combination thereof;
L is a divalent linker of 7 to 20 atoms in length, wherein the divalent linker comprises a divalent alkylene group, a cycloalkylenecarbonyl group and a hydrophobic side chain divalent group comprising an arylalkyl side chain; and
D is drug comprising a radioactive isotope of a metal coordinated to a chelating group,
the chelating group has the following formula
wherein * is the point of attachment to the divalent linker;
provided that the divalent linker has a single hydrophobic side chain divalent group in L.
2. The conjugate of claim 1 , or a salt thereof, wherein the ligand is a radical of the formula:
wherein X is RYP(S)(OH)CH 2 —; RYP(S)(OH)N(R 1 )—; RP(S)(OH)CH 2 —; RP(S)(OH)N(R 1 )—;
RP(S)(OH)O—; RYC(S)N(R 1 )—; RN(OH)C(S)Y; RC(S)NHY; RYP(S)(SH)CH 2 —;
RYP(S)(SH)N(R 1 )—; RP(S)(SH)CH 2 —; RP(S)(SH)N(R 1 )—; RP(S)(SH)S—; RN(SH)C(S)Y— or
RC(S)N(OH)Y, and the like; RS(O)Y, RSO 2 Y, RS(O)(NH)Y, and RS-alkyl,
wherein Y is independently selected in each instance from—CR 1 R 2 —, —NR 3 —, —S—, and −O—, wherein
R is a hydrogen, alkyl, aryl, or arylalkyl, each of which may be optionally substituted; and q is 0 to 5.
3. The conjugate of claim 1 , wherein the ligand is a prostate specific membrane antigen (PSMA) that is a thiourea of two amino acids, wherein the two amino acids are independently selected from asparagine, aspartic acid, cysteine, glutamic acid, lysine, glutamine, arginine, serine, ornithine, threonine, and combinations thereof.
4. The conjugate of claim 1 , or a salt thereof, wherein the chelating group is chelated to a radioactive metal isotope.
5. The conjugate of claim 1 , or a salt thereof, wherein the divalent linker is covalently bound to the chelating group through the formation of an amide bond, and the divalent linker is covalently bound to the ligand through the formation of an amide bond.
6. The conjugate of claim 1 , or a salt thereof, wherein L is covalently bound to B through an amide bond.
7. The conjugate of claim 1 , or a salt thereof, wherein L is covalently bound to the chelating group through a carbon-nitrogen single bond.
8. The conjugate of claim 2 , or a salt thereof, wherein the chelating group is chelated to a radioactive metal isotope.
9. The conjugate of claim 2 , or a salt thereof, wherein the divalent linker is covalently bound to the chelating group through the formation of an amide bond, and the divalent linker is covalently bound to the ligand through the formation of an amide bond.
10. The conjugate of claim 2 , or a salt thereof, wherein L is covalently bound to B through an amide bond.
11. The conjugate of claim 2 , or a salt thereof, wherein L is covalently bound to the chelating group through a carbon-nitrogen single bond.
12. The conjugate of claim 3 , or a salt thereof, wherein the chelating group is chelated to a radioactive metal isotope.
13. The conjugate of claim 3 , or a salt thereof, wherein the divalent linker is covalently bound to the chelating group through the formation of an amide bond, and the divalent linker is covalently bound to the ligand through the formation of an amide bond.
14. The conjugate of claim 3 , or a salt thereof, wherein L is covalently bound to B through an amide bond.
15. The conjugate of claim 3 , or a salt thereof, wherein L is covalently bound to the chelating group through a carbon-nitrogen single bond.
16. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , or a salt thereof, and a component selected from the group consisting of carriers, diluents, and excipients, and combinations thereof.
17. A method for treating a disease involving a pathogenic cell population expressing PSMA, the method comprising administering to a patient in need of relief from the disease a therapeutically effective amount of the conjugate of claim 1 , or a salt thereof, optionally with a component selected from the group consisting of carriers, diluents, excipients, and combinations thereof.